DOCSLIB.ORG

Lasofoxifene Cuts Fractures After Menopause

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lasofoxifene Cuts Fractures After Menopause 26 ENDOCRINOLOGY APRIL 15, 2010 • INTERNAL MEDICINE NEWS Lasofoxifene Cuts Fractures After Menopause ‘A significant effect … was not evident until 5 years, fractures also is similar to that observed treat 492 patients for 1 year to prevent a in women taking other antiresorptive single major coronary event,” she said. and absolute risk reductions were very small.’ therapies, and it stands in contrast to The PEARL investigators said that la- raloxifene’s inability to reduce this risk, sofoxifene raised the risk of venous BY MARY ANN MOON benefits over raloxifene for the skeleton, they said. thromboembolism to a similar degree as breast, heart, or reproductive tract. However, Dr. Becker noted in her ed- do raloxifene, tamoxifen, and oral estro- he investigational drug lasofox- “Given the plethora of drugs current- itorial that nearly all the reduction in gen therapies. Like these agents, laso- ifene decreases the risk of verte- ly available for osteoporosis, studies of risk for nonvertebral fractures could be foxifene also significantly increased the Tbral and nonvertebral fractures new agents should show clear benefits attributed to forearm and wrist frac- rate of hot flushes and leg cramps. It did in postmenopausal women with osteo- over existing agents,” she wrote. Results tures. “A significant effect in the overall not raise the risk of endometrial cancer porosis, according to a report. of the PEARL study do not do so, Dr. group was not evident until 5 years, and or endometrial hyperplasia. The nonsteroidal selective estrogen- Becker added. absolute risk reductions were very Dr. Becker countered that although receptor modulator (SERM) also reduces Dr. Cummings and his colleagues per- small. the increase in absolute risk of venous the risk of ER-positive breast cancer, formed the international, randomized, “On balance, lasofoxifene seems to of- thromboembolism was small, lasofox- major coronary heart disease events, and placebo-controlled PEARL study in 8,556 fer little, if any, advantage over raloxifene ifene more than doubled the relative stroke without raising the risk of en- women aged 59-80 years who had a bone as an agent against osteoporosis,” she risk. dometrial cancer or hyperplasia. mineral density T score of –2.5 or less at said (N. Engl. J. Med. 2010;362:752-4). In addition, rates of uterine polyps, en- Like other SERMs, lasofoxifene raises the lumbar spine or femoral neck. A to- Lasofoxifene also reduced the risk of dometrial hypertrophy, and vaginal can- the risk of venous thromboembolism tal of 28% already had at least one ver- ER-positive breast cancer by 85%, com- didiasis all were significantly higher than and increases the rate of hot flushes and tebral fracture at baseline. pared with placebo. Although this find- with placebo, she said. leg cramps, wrote Dr. Steven R. Cum- After 5 years of follow-up, women ing is “impressive,” it is similar to the risk Pfizer submitted a new drug applica- mings of California Pacific Medical Cen- who received 0.5 mg per day of lasofox- reduction reported for raloxifene, Dr. tion to the Food and Drug Administra- ter Research Institute, San Francisco, ifene showed a 42% reduction in relative Becker added. tion in 2007, and in 2008 an advisory pan- and his associates in the Postmenopausal risk for vertebral fractures and a 24% re- Lasofoxifene was associated with a el voted 9-3 that the benefits of the SERM Evaluation and Risk-Reduction with La- duction in relative risk for nonvertebral 32% reduction in relative risk of coro- outweighed this risk in postmenopausal sofoxifene (PEARL) study. fractures, compared with those who re- nary heart disease events (5.1 cases per women with osteoporosis. The FDA has Taken together, these findings seem to ceived placebo. 1,000 person-years) and a 36% reduction not yet issued a decision. ■ indicate that lasofoxifene performs Bone density at the lumbar spine, in relative risk of stroke (2.5 cases per somewhat better than do other SERMs femoral neck, and total hip improved by 1,000 person-years), compared with Disclosures: The PEARL study was such as raloxifene, and also has advan- about 3% with the active drug, the in- placebo (7.5 and 3.9 cases per 1,000 per- funded by Pfizer, manufacturer of tages over hormone therapy, tamoxifen, vestigators said (N. Engl. J. Med. son-years, respectively), Dr. Cummings lasofoxifene. Dr. Cummings reported and tibolone. 2010;362:686-96). and his associates said. receiving consulting fees from Amgen, Eli However, in an editorial accompany- This decrease in risk of vertebral frac- However, Dr. Becker noted that the Lilly, GlaxoSmithKline, and Organon, ing this report, Dr. Carolyn Becker of the tures is comparable with that reported number of these events was quite small, lecture fees from Eli Lilly and Novartis, and division of endocrinology, diabetes, and in women taking raloxifene, estrogen and there were no differences in rates of grant support from Amgen, Pfizer, and Eli hypertension at Brigham and Women’s therapy, oral bisphosphonates, and ti- fatal stroke. “Although the cardiovascu- Lilly. Dr. Becker’s financial disclosures are Hospital, Boston, argued that the drug bolone. lar benefits reported in the PEARL trial available with the text of the article at “offers no major clinically important The decrease in risk of nonvertebral seem impressive, one would need to NEJM.org. Role of Bisphosphonates in Atypical Fracture Downplayed BY SHARON WORCESTER Since radiographs in those with fractures were gen- While the current findings provide assurance that erally not available, atypical features—such as those as- these types of fractures are extremely rare, and that he risk of subtrochanteric and diaphyseal femur sociated with cortical thickness and fracture morphol- many more common and equally devastating hip frac- Tfractures is not significantly increased in women ogy—could not be assessed; if this information were tures are prevented than are caused by bisphosphonates, taking bisphosphonates, even among those treated for available, it is likely the femoral physicians should “reevaluate up to 10 years, a secondary analysis of data from three fracture rate would be even ‘Although we can confidently patients who are receiving large randomized bisphosphonate trials suggests. lower, they said. long-term bisphosphonate The findings follow several case reports that hinted at The findings support those conclude that absolute rates of therapy in the context of con- an increased risk of these atypical fractures in bisphos- from population base studied, such fractures are low, wide temporary guidelines for treat- phonate users. However, the current study, which in- including one that found evi- ment initiation, progress while cluded a review of 283 hip or femur fractures in 14,195 dence of an increased incidence confidence intervals ... preclude receiving therapy, current bone women with 51,287 patient-years of follow-up showed of hip and femur fractures with definitive conclusions regarding mineral density measurement, that only 12 subtrochanteric or diaphyseal femur frac- alendronate use, but which at- and risk factors for fracture,” tures occurred in 10 women, for a rate of 2.3 per 10,000 tributed that to the increased the relative risk of treatment.’ wrote Dr. Shane of Columbia patient-years, Dennis M. Black, Ph.D., of the University use of alendronate in high-risk University, New York (N. Engl. of California at San Francisco and his colleagues wrote. patients rather than to the use of alendronate. J. Med. 2010 March 24 [doi:10.1056/NEJMe1003064]). The data analyzed in the current study were from the “Although we can confidently conclude that absolute It is reasonable to consider drug holidays, particu- phase III Fracture Intervention Trial (FIT), the FIT rates of such fractures are low, wide confidence inter- larly in those with substantially reduced levels of Long-Term Extension (FLEX) trial, and the Health vals (resulting from the very low incidence of events) bone turnover markers, but again, the evidence of per- Outcomes and Reduced Incidence with Zoledronic preclude definitive conclusions regarding the relative sistent antifracture efficacy after discontinuation must Acid Once Yearly Pivotal Fracture Trial (HORIZON- risk of treatment,” the investigators wrote. be balanced with data showing that 10 vs. 5 years of PFT); the relative hazard ratios for subtrochanteric and However, based on data they analyzed, the investi- alendronate use is associated with significantly fewer diaphyseal femur fractures were 1.03 for alendronate vs. gators estimated that 3 years of bisphosphonate treat- new vertebral and nonvertebral fractures in those placebo in the FIT trial, 1.50 for zoledronic acid vs. ment in 1,000 women with osteoporosis would prevent with bone mineral density T scores of –2.5 or lower, placebo in the HORIZON-PFT trial, and 1.33 for con- about 100 fractures, including 71 vertebral fractures and she wrote. ■ tinued alendronate use vs. placebo in the FLEX trial, the 29 nonvertebral fractures, including 11 hip fractures. investigators reported (N. Engl. J. Med. 2010 March 24 Balanced against the annual rate of 2.3 subtrochanteric Disclosures: This study was supported by Merck and [doi:10.1056/NEJMoa1001086]). and diaphyseal femur fractures seen in the three trials, Novartis. The investigators reported receiving grants, Even in the FLEX trial, which included up to 10 years “the hypothetical risk is quite small,” they concluded. travel reimbursement, consulting fees, and lecture fees from of treatment with alendronate, the risk of femur frac- Additional research is needed to more fully address Merck, Novartis, and several other pharmaceutical ture and atypical femur fracture was very low, with no the matter of bisphosphonate use and the risk of sub- manufacturers, as well as the National Osteoporosis significantly increased risk of fracture among those who trochanteric and diaphyseal fractures, Dr. Elizabeth Foundation. Dr. Shane reported receiving grants from continued treatment for the full 10 years, they wrote.
Load more

Recommended publications
  • 1 Disposition of Lasofoxifene, a Next Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects Chandra Prakash
    DMD Fast Forward. Published on March 27, 2008 as DOI: 10.1124/dmd.108.020404 DMD FastThis article Forward. has not beenPublished copyedited on and March formatted. 27, The 2008 final version as doi:10.1124/dmd.108.020404 may differ from this version. “DMD #20404” DISPOSITION OF LASOFOXIFENE, A NEXT GENERATION SELECTIVE ESTROGEN RECEPTOR MODULATOR, IN HEALTHY MALE SUBJECTS CHANDRA PRAKASH, KIM A JOHNSON AND MARK J GARDNER, Pfizer Global Research and Development, Groton, CT, USA Downloaded from dmd.aspetjournals.org at ASPET Journals on September 24, 2021 1 Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on March 27, 2008 as DOI: 10.1124/dmd.108.020404 This article has not been copyedited and formatted. The final version may differ from this version. “DMD #20404” Running title: In vivo and in vitro metabolism of lasofoxifene Address for Correspondence: Chandra Prakash, Ph. D. Pharmacokinetics, Dynamics and Metabolism Pfizer Global Research and Development Downloaded from Groton, CT 06340 Ph. No. 860-441-6415 Fax No. 860-686-0654 dmd.aspetjournals.org email: [email protected] Text pages 33 at ASPET Journals on September 24, 2021 Tables 4 Figures 9 References 31 Abstract 245 Introduction 484 Discussion 1487 1 Abbreviations used are: SERM, selective estrogen receptor modulator; EPT, estrogen- progestin replacement therapy; ER, estrogen receptor; SRM, single reaction monitoring; SAM, S-adenosyl methionine; ABT, aminobenzotriazole; ICH, international conference on harmonization; GCP, Good Clinical Practices; MTBE, methyl-tert-butyl ether; COMT, catechol-O-methyltransferase; UGT, UDP-glucuronosyltransferase; UDPGA, UDP- glucuronic acid. 2 DMD Fast Forward.
    [Show full text]
  • Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS)
    Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS) - a revival? Rozenberg S, Eyckerman M Homepage: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen www.kup.at/ 2011; 18 (Sonderheft 2), 4-5 mineralstoffwechsel Online-Datenbank mit Autoren- und Stichwortsuche Member of the Offizielles Organ der Österreichische Gesellschaft Österreichische Indexed in SCOPUS/EMBASE/Excerpta Medica Österreichischen Gesellschaft für Orthopädie und Gesellschaft zur Erforschung des Knochens Orthopädische Chirurgie für Rheumatologie www.kup.at/mineralstoffwechsel und Mineralstoffwechsels P.b.b. GZ02Z031108M, Verlagspostamt: 3002 Purkersdorf, Erscheinungsort: 3003 Gablitz P.b.b. GZ02Z031108M, Verlagspostamt: 3002 Purkersdorf, Erscheinungsort: 3003 Gablitz Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS) – a revival? S. Rozenberg, M. Eyckerman This review analyses the efficacy of selective estrogen-receptor 0.89) [5]. In the STAR-study (Tam versus RAL in 19,647 post- modulators (SERMs) in postmenopausal osteoporosis treatment menopausal women with increased 5-year breast cancer risk), based on meta-analyses or randomized controlled trials (RCTs). RAL was shown to be as effective as tamoxifen in reducing the We also refer to a consensus paper [1]. risk of invasive breast cancer but not non-invasive breast can- cer, but RAL was associated with a higher safety (lower risk of thromboembolic events and cataracts) [7]. A more recent meta- ! Tibolone analysis by Kanis et al [8] evaluated the distribution of fracture risk assessed at baseline using the FRAX tool in RCT with RAL Tibolone is viewed by some as a menopause hormone therapy in the MORE-trial and determined the efficacy of RAL as a rather than as a SERM.
    [Show full text]
  • Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
    Published OnlineFirst March 27, 2013; DOI: 10.1158/1078-0432.CCR-12-3771 Clinical Cancer Cancer Therapy: Preclinical Research Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease Suzanne E. Wardell, Erik R. Nelson, Christina A. Chao, and Donald P. McDonnell Abstract Purpose: There is compelling evidence to suggest that drugs that function as pure estrogen receptor (ER-a) antagonists, or that downregulate the expression of ER-a, would have clinical use in the treatment of advanced tamoxifen- and aromatase-resistant breast cancer. Although such compounds are currently in development, we reasoned, based on our understanding of ER-a pharmacology, that there may already exist among the most recently developed selective estrogen receptor modulators (SERM) compounds that would have usage as breast cancer therapeutics. Thus, our objective was to identify among available SERMs those with unique pharmacologic activities and to evaluate their potential clinical use with predictive models of advanced breast cancer. Experimental Design: A validated molecular profiling technology was used to classify clinically relevant SERMs based on their impact on ER-a conformation. The functional consequences of these observed mechanistic differences on (i) gene expression, (ii) receptor stability, and (iii) activity in cellular and animal models of advanced endocrine-resistant breast cancer were assessed. Results: The high-affinity SERM bazedoxifene was shown to function as a pure ER-a antagonist in cellular models of breast cancer and effectively inhibited the growth of both tamoxifen-sensitive and -resistant breast tumor xenografts. Interestingly, bazedoxifene induced a unique conformational change in ER-a that resulted in its proteasomal degradation, although the latter activity was dispensable for its antagonist efficacy.
    [Show full text]
  • David J. Portman, M.D. Page 1
    David J. Portman, M.D. Page 1 Version Date Nov 1st, 2016 David J. Portman, M.D. Sermonix Pharmaceutical LLC 99 North Brice Road Suite 120 Columbus, Ohio 43213 Phone (614) 864-4919 Fax (614) 864-4928 [email protected] PERSONAL Founder, CEO and Medical Director of Sermonix Pharmaceuticals Director Emeritus of a Clinical Research Center with research interests in menopause, sexual dysfunction, hormone replacement therapy, SERMs, osteoporosis, contraception and gynecologic endocrinology. Conducted over 140 clinical trials in women’s health. Lectures nationally, internationally and consults widely on women’s health issues, and is on numerous advisory boards. Board-certified Obstetrician/Gynecologist. EDUCATION B.A. in History and Premedicine, Northwestern University, Evanston, Illinois, 1984 M.D. The Ohio State University College of Medicine, Columbus, 1990 OB/GYN Post-Graduate Residency, Ohio State University Hospitals, Columbus, 1994 EMPLOYMENT Present Founder, CEO and Chief Medical Officer of Sermonix Pharmaceuticals, an Ohio LLC specialty pharmaceutical company with targeted focus towards bringing new and emerging late-stage women’s health products through clinical development, regulatory approval, and commercialization. 1997-Present Founder, Director Emeritus, Principal Investigator, The Columbus Center for Women’s Health Research - An independent private research center dedicated to innovation in the medical treatment of women, participating in Phase II-IV clinical trial research 1994-2015 Portman Obstetrics and Gynecology, Associates Private Practice 1994-Present Adjunct Instructor, Department of OB/GYN Wexner Medical Center at The Ohio State University and lecturer in the Department of Medical Humanities David J. Portman, M.D. Page 2 1995-2008 Founder and President, Ob/Gyn Physician Services, Inc.
    [Show full text]
  • Design and Synthesis of Selective Estrogen Receptor Β Agonists and Their Hp Armacology K
    Marquette University e-Publications@Marquette Dissertations (2009 -) Dissertations, Theses, and Professional Projects Design and Synthesis of Selective Estrogen Receptor β Agonists and Their hP armacology K. L. Iresha Sampathi Perera Marquette University Recommended Citation Perera, K. L. Iresha Sampathi, "Design and Synthesis of Selective Estrogen Receptor β Agonists and Their hP armacology" (2017). Dissertations (2009 -). 735. https://epublications.marquette.edu/dissertations_mu/735 DESIGN AND SYNTHESIS OF SELECTIVE ESTROGEN RECEPTOR β AGONISTS AND THEIR PHARMACOLOGY by K. L. Iresha Sampathi Perera, B.Sc. (Hons), M.Sc. A Dissertation Submitted to the Faculty of the Graduate School, Marquette University, in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Milwaukee, Wisconsin August 2017 ABSTRACT DESIGN AND SYNTHESIS OF SELECTIVE ESTROGEN RECEPTOR β AGONISTS AND THEIR PHARMACOLOGY K. L. Iresha Sampathi Perera, B.Sc. (Hons), M.Sc. Marquette University, 2017 Estrogens (17β-estradiol, E2) have garnered considerable attention in influencing cognitive process in relation to phases of the menstrual cycle, aging and menopausal symptoms. However, hormone replacement therapy can have deleterious effects leading to breast and endometrial cancer, predominantly mediated by estrogen receptor-alpha (ERα) the major isoform present in the mammary gland and uterus. Further evidence supports a dominant role of estrogen receptor-beta (ERβ) for improved cognitive effects such as enhanced hippocampal signaling and memory consolidation via estrogen activated signaling cascades. Creation of the ERβ selective ligands is challenging due to high structural similarity of both receptors. Thus far, several ERβ selective agonists have been developed, however, none of these have made it to clinical use due to their lower selectivity or considerable side effects.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Lasofoxifene (tartrate) Item No. 17646 CAS Registry No.: 190791-29-8 Formal Name: (5R,6S)-5,6,7,8-tetrahydro-6-phenyl- N 5-[4-[2-(1-pyrrolidinyl)ethoxy] phenyl]-2-naphthalenol, (2S,3S)-2,3- O dihydroxybutanedioate Synonym: CP 336,156 • C4H6O6 MF: C28H31NO2 • C4H6O6 FW: 563.6 Purity: ≥98% Supplied as: A crystalline solid OH Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Lasofoxifene (tartrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the lasofoxifene (tartrate) in the solvent of choice. Lasofoxifene (tartrate) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of lasofoxifene (tartrate) in these solvents is approximately 1 mg/ml. Lasofoxifene (tartrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lasofoxifene (tartrate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Lasofoxifene (tartrate) has a solubility of approximately 0.25 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Lasofoxifene is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). It 1 selectively binds to human ERα with an IC50 value of 1.5 nM and inhibits bone loss in ovariectomized rats. In clinical studies of postmenopausal osteoporosis, 0.5 mg/day lasofoxifene was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.2,3 Lasofoxifene has also been shown to act as an inverse agonist at the CB2 cannabinoid receptor, indicating its potential to be repurposed as a therapeutic 4 for indications wherein CB2 is a target.
    [Show full text]
  • Reference List Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S
    SERM Education Project Reference List Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014;78(3):212-218. Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause. 2015;22(7):786-796. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92(3):1039-1044. Archer DF. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause. 2011;18(1):6-7. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmentopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132-140. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA) [abstract]. Menopause. 2005;12(2):238. Bachmann G, Gass M, Moffett A, Portman D, Symons J. Lasofoxifene improves symptoms associated with vaginal atrophy [abstract]. Menopause. 2004;11(6):669. Abstract P-63. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-486. Barrett-Connor E, Grady D, Sashegyi A, et al; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    [Show full text]
  • The PEARL Trial: Lasofoxifene and Incidence of Fractures, Breast Cancer and Cardiovascular Events in Postmenopausal Osteoporotic Women
    CLINICAL TRIAL REPORT Vukicevic & Grgurevic CLINICAL TRIAL REPORT The PEARL trial: lasofoxifene and incidence of fractures, breast cancer and cardiovascular events in postmenopausal osteoporotic women Lasofoxifene is a selective estrogen-receptor modulator with high affinity and selectivity for estrogen receptors, leading to estrogen-agonist effects in some tissues and estrogen-antagonist effects in others. Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) was a global, multicenter, double-blind, placebo-controlled randomized trial which recruited 8556 women between 59–80 years of age with osteoporosis under therapy with lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. In postmenopausal women with osteoporosis, lasofoxifene 0.5 mg/day for 5 years reduced the risk of nonvertebral and vertebral fractures, major coronary heart disease, stroke and both total and estrogen receptor-positive invasive breast cancer risk. However, both doses of lasofoxifene increased the risk of venous thromboembolic events. †1 KEYWORDS: estrogen receptor-positive breast cancer n fracture n heart disease Slobodan Vukicevic n osteoporosis n PEARL trial & Lovorka Grgurević1 1Laboratory for Mineralized Tissues, School of Medicine, University Selective Estrogen-Receptor Modulators (SERMs) the hip and spine as well as reduced the bone of Zagreb, Salata 11, are a class of compounds that act on the estrogen turnover [9]. Previous randomized trials of tamox- 10000 Zagreb, Croatia †Author for correspondence: receptors (ERs). Lasofoxifene is a nonsteroidal- ifen [10,11] and raloxifene [12,13] have reported no Tel.: +385 1456 6812 selective ER modulator that decreases bone rea- benefit on the risk of coronary heart disease Fax: +385 1456 6822 sorption, bone loss and low density lipoprotein events and an increased risk of venous thrombo- [email protected] (LDL) cholesterol in postmenopausal women [1].
    [Show full text]
  • 022247Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022247Orig1s000 PHARMACOLOGY REVIEW(S) NDA 22247 Duavee (conjugated estrogens/bzedoxifene) tablets Comments from A. Jacobs, AD Date Oct 2, 2013 1. I concur that there are no outstanding pharm/tox issues. 2. I concur that the pregnancy labeling is appropriate 3. I have previously conveyed comments to the pharm/tox reviewer on the pharm/tox review and labeling, and they have been addressed as appropriate. Reference ID: 3382471 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- ABIGAIL C JACOBS 10/02/2013 Reference ID: 3382471 DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION Application number: 22-247 Supporting document/s: SDN #1 Applicant’s letter date: October 3, 2012 CDER stamp date: October 3, 2012 Product: Bazedoxifene and conjugated estrogens Vasomotor symptoms, vulvar vaginal atrophy Indication: and prevention of osteoporosis in postmenopausal women Wyeth Pharmaceuticals Inc. Applicant: Wholly owned subsidiary of Pfizer Inc. Review Division: Division of Reproductive and Urologic Drugs Reviewer:
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive
    Author Manuscript Published OnlineFirst on April 19, 2018; DOI: 10.1158/1078-0432.CCR-18-0759 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive V. Craig Jordan Running Title Antihormone resistance Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston, Texas USA Conflict of interest statement: None to report Funding acknowledgment: This work was supported by the University of Texas MD Anderson Cancer Center support grant to Peter Pisters CA 016672, the benefactors of the Dallas/Ft Worth Living Legend Chair of Cancer Research, and the George and Barbara Bush Endowment for Innovative Cancer Research. Corresponding Author: V. Craig Jordan, OBE, Ph.D, DSc, FMedSci, FAACR Dallas/Ft. Worth Living Legend Chair of Cancer Research Professor of Breast Medical Oncology Professor of Molecular and Cellular Oncology Chief, Section of Basic Science Research and Pharmacology Member of the National Academy of Sciences Member of the National Academy of Medicine University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd., Unit 1354 Houston, TX 77030 T: 713-745-0600 F: 713-794-4385 [email protected] 1 Downloaded from clincancerres.aacrjournals.org on October 4, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 19, 2018; DOI: 10.1158/1078-0432.CCR-18-0759 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Summary Predictive tests, to refine the estrogen receptor assay, for the adjuvant treatment of breast cancer with tamoxifen and oral Selective Estrogen Receptor Degraders (SERDs) are required.
    [Show full text]
  • A Potential Option for Non-Binary Gender-Affirming Hormonal Care?
    PERSPECTIVE published: 18 June 2021 doi: 10.3389/fendo.2021.701364 Selective Estrogen Receptor Modulators: A Potential Option For Non-Binary Gender-Affirming Hormonal Care? Jane Y. Xu 1, Michele A. O’Connell 2,3,4, Lauren Notini 2,5, Ada S. Cheung 6, Sav Zwickl 6 and Ken C. Pang 2,3,4* 1 Geisel School of Medicine, Dartmouth College, Hanover, NH, United States, 2 Clinical Sciences and Genetics Themes, Murdoch Children’s Research Institute, Parkville, VIC, Australia, 3 Department of Adolescent Medicine, Royal Children’s Hospital, Melbourne, VIC, Australia, 4 Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia, 5 Melbourne Law School, University of Melbourne, Parkville, VIC, Australia, 6 Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Heidelberg, VIC, Australia Gender dysphoria describes the distress associated with having a gender identity that differs from one’s birth-assigned sex. To relieve this distress, transgender, and gender diverse (henceforth, trans) individuals commonly undergo medical transition involving hormonal treatments. Current hormonal treatment guidelines cater almost exclusively for Edited by: those who wish to transition from male to female or vice versa. In contrast, there is a dearth ´ Rosa Fernandez, of hormonal options for those trans individuals who identify as non-binary and seek an University of A Coruña CICA-INIBIC Strategic Group, Spain androgynous appearance that is neither overtly male nor female. Though prolonged Reviewed by: puberty suppression with gonadotrophin releasing hormone agonists (GnRHa) could in Mireia Mora Porta, theory be gender-affirming by preventing the development of unwanted secondary sex Hospital Cl´ınic de Barcelona, Spain Irene Halperin Rabinovich, characteristics, this treatment option would be limited to pre- or peri-pubertal adolescents Hospital Cl´ınic, Spain and likely have harmful effects.
    [Show full text]